Skip to content

GLP-1 side effects: what the FDA labels report

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

The most common GLP-1 side effects are stomach and bowel reactions: nausea, diarrhea, vomiting, constipation and abdominal pain. The FDA labels for Zepbound, Mounjaro, Foundayo, Trulicity, Wegovy, Ozempic, Rybelsus and Saxenda all report them. Several labels say these happen mostly while the dose is being raised. All eight carry a boxed warning about thyroid C-cell tumors.

Source: U.S. Food and Drug Administration

Key takeaways

  • Nausea, diarrhea and vomiting are on all eight labels, and several tie them to dose increases.
  • These medicines are not to be used with a personal or family history of medullary thyroid carcinoma or MEN 2.
  • Persistent or severe abdominal pain is a reason to contact a doctor promptly. Don't wait for your next appointment.
  • Multi-dose pens must not be shared, even with a new needle.
  • If you think you're having a medical emergency, call 911.

Every figure on this page and the ten pages under it comes from the adverse reactions and warnings sections of the FDA labels, as published on DailyMed. We cover eight medicines: Zepbound, Mounjaro, Foundayo, Trulicity, Wegovy, Ozempic, Rybelsus and Saxenda. When a label is silent on something, we say so. We don’t fill the gap.

This page tells you what the labels report. It isn’t a way to judge your own symptoms, and nothing here is a reason to change or skip a dose. Those decisions belong with your prescriber.

What are the most common GLP-1 side effects?

Stomach and bowel reactions, in every label. The labels call these gastrointestinal reactions. Each label states how many trial patients reported any gastrointestinal reaction, next to the placebo group in the same trials. A placebo group gets an inactive treatment instead of the medicine.

  • Zepbound (adults with obesity or overweight, two pooled weight reduction trials): 56% at each of the 5 mg, 10 mg and 15 mg doses, 30% on placebo.
  • Mounjaro (adults with type 2 diabetes, pooled placebo-controlled trials): 37.1% at 5 mg, 39.6% at 10 mg and 43.6% at 15 mg, 20.4% on placebo.
  • Foundayo (adults with obesity or overweight, two pooled trials): 60% at 5.5 mg, 68% at 9 mg and 69% at 17.2 mg, 37% on placebo.
  • Trulicity (adults with type 2 diabetes, pooled placebo-controlled trials): 32% at 0.75 mg and 41% at 1.5 mg, 21% on placebo.
  • Wegovy injection (adults, weight reduction trials): 73%, against 47% on placebo.
  • Ozempic injection (adults with type 2 diabetes): 32.7% at 0.5 mg and 36.4% at 1 mg, 15.3% on placebo.
  • Rybelsus (adults with type 2 diabetes; the same label covers Ozempic tablets): 32% at 7 mg and 41% at 14 mg, 21% on placebo.
  • Saxenda (adults, weight management trials): approximately 68%, against 39% on placebo.

Look at the placebo numbers before anything else. Between 15.3% and 47% of people taking a placebo reported a gastrointestinal reaction, depending on the trial. A label percentage is the share of people who reported the reaction while on the medicine. It isn’t the share whose reaction was caused by it.

Each reaction has its own page with the label tables, dose group by dose group:

Can you compare side effect rates between GLP-1 medicines?

No, and we don’t rank the medicines by tolerability (how well people handle them). The trials behind each label were run separately, in different people, for different lengths of time, with different rules about what goes in the table.

The list above shows the problem. The Zepbound, Foundayo, Wegovy and Saxenda figures come from weight management trials. The Mounjaro, Trulicity, Ozempic and Rybelsus figures come from type 2 diabetes trials. The placebo groups alone range from 15.3% to 47%, which tells you the trials were counting in different settings. A higher number on one label than another doesn’t show that one medicine is harder to tolerate.

What you can do is read each medicine against its own placebo group. That’s how the label presents it, and how our reaction pages present it.

Do side effects get worse when the dose goes up?

The labels link stomach reactions to the weeks when the dose is being increased, which they call dose escalation. That’s the reason every one of these medicines starts low and steps up.

  • Zepbound’s label says the majority of nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time.
  • Foundayo’s label says the incidence of nausea, vomiting and diarrhea was higher during the dosage escalation period and decreased over time.
  • The Ozempic label and the Rybelsus label each say the majority of reports of nausea, vomiting and diarrhea occurred during dose escalation.
  • Wegovy’s label says gastrointestinal reactions were most frequently reported during dosage escalation, and its dosing section says to follow the escalation schedule “to reduce the risk of gastrointestinal adverse reactions.”
  • Saxenda’s label says the percentage of patients reporting nausea declined as treatment continued.

The labels don’t say that a reaction will pass, or by when. To see when each step up falls on the calendar, the titration schedule tool lays out the label’s dose path for your medicine. How fast to move through it, and whether to stay longer on a dose, is a decision your prescriber makes.

How many people stop treatment because of side effects?

A minority, and more than on placebo. Here are a few examples of what the labels report for stopping because of gastrointestinal reactions:

  • Zepbound: 1.9% at 5 mg, 3.3% at 10 mg and 4.3% at 15 mg, against 0.5% on placebo.
  • Foundayo: 3% at 5.5 mg, 6% at 9 mg and 6% at 17.2 mg, against 0.7% on placebo.
  • Saxenda: 6.2%, against 0.8% on placebo. The same sentence of the label says most gastrointestinal episodes were mild or moderate.

Foundayo’s label also breaks down severity. Of the patients on Foundayo who reported a gastrointestinal reaction, 60% described it as mild, 36% as moderate and 4% as severe.

What is the boxed warning on GLP-1 medicines?

All eight labels carry a boxed warning titled “Risk of Thyroid C-Cell Tumors.” A boxed warning is the strongest kind the FDA requires, set apart in a box on the label.

Seven of the labels say the same thing in substance. The drug caused thyroid C-cell tumors in rodents (tirzepatide for Zepbound and Mounjaro, semaglutide for Wegovy, Ozempic and Rybelsus, dulaglutide for Trulicity, liraglutide for Saxenda). It’s unknown whether the medicine causes these tumors, including medullary thyroid carcinoma (MTC), in humans, because the human relevance of the rodent finding hasn’t been determined.

Foundayo’s wording differs. Its boxed warning says rodent thyroid C-cell tumors have been observed with products that have GLP-1 receptor agonist activity, and that orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents.

For all eight, the consequence is the same contraindication, which means a situation where a medicine must not be used. The medicine is not to be used by people with a personal or family history of MTC or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). If either applies to you or your family, tell your prescriber before starting.

What other warnings do the labels carry?

Beyond the boxed warning, the warnings and precautions sections repeat a common set across the eight labels. In plain words:

  • Acute pancreatitis. Inflammation of the pancreas, including fatal cases, has been observed with medicines of this kind. The labels say the medicine should be discontinued if pancreatitis is suspected.
  • Severe gastrointestinal reactions. Stomach and bowel reactions are sometimes severe. The Zepbound, Mounjaro, Foundayo and Trulicity labels, among others, say the medicine is not recommended in people with severe gastroparesis (a stomach that empties very slowly).
  • Acute kidney injury from dehydration. Zepbound’s label, like the others, describes postmarketing reports (reports made after approval) of acute kidney injury, in some cases requiring hemodialysis. It says the majority occurred in patients whose nausea, vomiting or diarrhea led to dehydration.
  • Acute gallbladder disease. Gallstones and gallbladder inflammation have been reported in trials and after approval.
  • Hypoglycemia. The risk of low blood sugar is higher when the medicine is used with insulin or a sulfonylurea.
  • Serious allergic reactions. Anaphylaxis and angioedema have been reported.
  • Diabetic retinopathy complications in people with type 2 diabetes, particularly those with a history of retinopathy. Seven labels carry this warning.
  • NAION, a rare eye condition. In November 2026, FDA said GLP-1 receptor agonists carry a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), which can cause sudden, painless loss of vision in one eye, sometimes permanently. FDA is requiring all eight labels, and every other GLP-1 label, to add this warning. Contact your healthcare professional right away if the vision in one eye suddenly changes.
  • Pulmonary aspiration during anesthesia or deep sedation. These medicines slow stomach emptying, and there have been rare reports of stomach contents entering the lungs during procedures.
  • Heart rate increase, a named warning on the Wegovy and Saxenda labels.
  • Never share a pen. The multi-dose pens (Ozempic, the Wegovy FlexTouch, the Zepbound and Mounjaro KwikPens) must not be shared, even with a new needle.

Each drug guide shows that label’s own warnings in full: Zepbound, Mounjaro, Foundayo, Trulicity, Wegovy, Ozempic, Rybelsus and Saxenda.

When do the labels say to call a doctor or get emergency help?

The label text we hold is written for prescribers, so most of it says what the clinician should watch for. Read from your side, it points to these situations:

  • Persistent or severe abdominal pain. Wegovy’s label describes the signs of acute pancreatitis as “persistent or severe abdominal pain (sometimes radiating to the back),” with or without nausea or vomiting, and says the medicine should be discontinued if pancreatitis is suspected. Contact a doctor promptly. Do not wait for the next appointment.
  • Signs of a serious allergic reaction. Foundayo’s label says to advise the patient “to promptly seek medical attention.” Saxenda’s says the patient should stop the medicine and “promptly seek medical advice.”
  • Vomiting or diarrhea you can’t keep up with. Dehydration is the route to the kidney injuries the labels describe. So Wegovy’s label tells prescribers to monitor kidney function in patients reporting reactions that could lead to volume depletion (losing too much fluid), especially while starting and escalating the dose. Your prescriber can only do that if you report it.
  • Before surgery or a procedure with sedation. The Wegovy label says to inform healthcare providers before any planned surgery or procedure that you’re taking the medicine. The Ozempic, Rybelsus and Saxenda labels say the same.

If you think you’re having a medical emergency, call 911. For anything short of that, your prescriber or pharmacist is the right first call, and they can tell you whether a dose should be held. Do not make that decision from a web page.

Is it a side effect or a dosing mistake?

Sometimes a bad reaction traces back to the amount taken, not the medicine itself. That risk is highest with vials and syringes, where milligrams, milliliters and syringe units are easy to confuse. The dosing error checker explains the difference between those units and what to do if you think you took the wrong amount.

How to read the reaction pages

All ten pages follow the same order. First come the labels that list the reaction in their tables and at what rate, with the dose group, the placebo figure and the trial population. Next come the labels that don’t list it. Then you’ll see what the labels say about timing, the warnings that relate to it, and when to contact your prescriber.

Two reading rules apply everywhere. First, “not listed in the label’s table” means only that. Tables have cutoffs: each lists only reactions reported by a minimum share of patients, and the minimum differs from label to label. So a missing row isn’t evidence that a medicine can’t cause the reaction. Second, a postmarketing report is a reaction reported after approval, from a population of unknown size. The labels say that for such reports it’s not always possible to estimate frequency or establish that the drug was the cause.

Frequently asked questions

What are the most common side effects of GLP-1 medicines?

Stomach and bowel reactions. All eight FDA labels we track put nausea, diarrhea and vomiting in their tables of common adverse reactions (side effects), and most add constipation, abdominal pain and dyspepsia (indigestion). Fatigue, headache, hair loss and injection site reactions appear in some tables and not others. Each label's numbers come from its own trials, so you can't compare the percentages across medicines.

What are the side effects of Ozempic?

The Ozempic injection label's table lists nausea, vomiting, diarrhea, abdominal pain and constipation in adults with type 2 diabetes. In its placebo-controlled trials, gastrointestinal (stomach and bowel) reactions overall were reported by 32.7% of patients on 0.5 mg and 36.4% on 1 mg, against 15.3% on placebo. The label has a boxed warning about thyroid C-cell tumors, plus warnings that include pancreatitis and diabetic retinopathy complications.

What are the side effects of Zepbound?

In Zepbound's two pooled weight reduction trials, gastrointestinal (stomach and bowel) reactions were reported by 56% of patients at each dose (5 mg, 10 mg and 15 mg) and 30% on placebo. The label's table also lists injection site reactions, fatigue, hair loss, dizziness and others. The label says most nausea, vomiting and diarrhea events occurred during dose escalation (while the dose was being raised) and decreased over time.

What are the side effects of Mounjaro?

In Mounjaro's pooled placebo-controlled trials in adults with type 2 diabetes, gastrointestinal (stomach and bowel) reactions were reported by 37.1% of patients on 5 mg, 39.6% on 10 mg and 43.6% on 15 mg, against 20.4% on placebo. The label has the boxed warning about thyroid C-cell tumors, and it says the medicine is not recommended in people with severe gastroparesis (a stomach that empties very slowly).

Do GLP-1 side effects go away?

The labels describe a pattern, not a promise. Zepbound's says most nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time. Foundayo's says the incidence was higher during dosage escalation and decreased over time. Saxenda's says the percentage of patients reporting nausea declined as treatment continued. If a reaction doesn't ease, talk to your prescriber.

Do side effects get worse at higher doses?

The labels tie stomach effects to the period when the dose is being raised more than to any one dose. Wegovy's label says to follow its dosage escalation schedule to reduce the risk of gastrointestinal adverse reactions. Whether a higher dose group reported more of a given reaction varies by medicine and by reaction. The label tables on each of our reaction pages show this group by group.

What is the boxed warning on GLP-1 medicines?

It's about thyroid C-cell tumors. The labels state that the drug, or drugs of its kind, caused these tumors in rodents, and that it's unknown whether the medicine causes them, including medullary thyroid carcinoma, in humans. Each of the eight medicines is contraindicated (must not be used) in people with a personal or family history of medullary thyroid carcinoma or with MEN 2.

Can GLP-1 medicines cause pancreatitis?

Every label we track has an acute pancreatitis warning. Wegovy's describes the signs as persistent or severe abdominal pain, sometimes radiating to the back, which may or may not come with nausea or vomiting. It says the medicine should be discontinued if pancreatitis is suspected. That kind of pain is a reason to contact a doctor promptly, not something to wait out.

Do GLP-1 medicines cause hair loss?

Hair loss is listed in the clinical trial tables of the Zepbound, Wegovy and Foundayo labels, the three with weight reduction trials in their tables. The Zepbound and Foundayo labels state that hair loss reactions were associated with weight reduction. The Mounjaro, Trulicity, Ozempic, Rybelsus and Saxenda labels list alopecia (hair loss) only as a postmarketing report, with no rate. Our hair loss page has the figures.

When should I call a doctor about a GLP-1 side effect?

The warnings in the labels point to several situations: persistent or severe abdominal pain, signs of a serious allergic reaction, and stomach reactions severe enough to leave you dehydrated, since dehydration has led to acute kidney injury. Foundayo's label says to seek medical attention promptly for a hypersensitivity (allergic) reaction. If you think you're having an emergency, call 911.

Sources (33)

  1. 1.
    Zepbound prescribing information, section 6.1 (gastrointestinal adverse reactions)
    “In a pool of Study 1 and 2, gastrointestinal adverse reactions occurred more frequently among patients receiving ZEPBOUND (5 mg 56%, 10 mg 56%, 15 mg 56%) than placebo (30%). More patients receiving ZEPBOUND 5 mg (1.9%), ZEPBOUND 10 mg (3.3%), and ZEPBOUND 15 mg (4.3%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.5%). The majority of nausea, vomiting, and/or diarrhea events occurred during dose escalation and decreased over time.”
  2. 2.
    Zepbound prescribing information, boxed warning
    “In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions (5.1) and Nonclinical Toxicology (13.1)].”
  3. 3.
    Zepbound prescribing information, section 5 (acute kidney injury due to volume depletion)
    “There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists, or ZEPBOUND [see Adverse Reactions (6.2)]. The majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea [see Adverse Reactions (6.1)].”
  4. 4.
    Mounjaro prescribing information, section 6.1 (gastrointestinal adverse reactions)
    “In the pool of placebo-controlled trials in adults, gastrointestinal adverse reactions occurred more frequently among patients receiving MOUNJARO than placebo (placebo 20.4%, MOUNJARO 5 mg 37.1%, MOUNJARO 10 mg 39.6%, MOUNJARO 15 mg 43.6%).”
  5. 5.
    Foundayo prescribing information, section 6.1 (gastrointestinal adverse reactions)
    “In a pool of Trials 1 and 2, gastrointestinal adverse reactions occurred more frequently among patients treated with once daily FOUNDAYO 5.5 mg (60%), 9 mg (68%), and 17.2 mg (69%) than placebo (37%). More patients treated with once daily FOUNDAYO 5.5 mg (3%), 9 mg (6%), and 17.2 mg (6%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.7%).”
  6. 6.
    Foundayo prescribing information, section 6.1 (severity and timing of gastrointestinal reactions)
    “Of the FOUNDAYO-treated patients who reported GI adverse reactions, 60%, 36%, and 4% reported mild or moderate or severe adverse reactions, respectively. The incidence of nausea, vomiting, and diarrhea was higher during the FOUNDAYO dosage escalation period and decreased over time.”
  7. 7.
    Foundayo prescribing information, boxed warning
    “In products with glucagon-like peptide-1 (GLP-1) receptor agonist activity that are pharmacologically active in rats and mice, rodent thyroid C-cell tumors (adenomas and carcinomas) have been observed at clinically relevant exposures and are considered GLP-1 receptor-dependent effects in rodents. Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents [see Nonclinical Toxicology (13.1)].”
  8. 8.
    Foundayo prescribing information, section 5 (hypersensitivity reactions)
    “Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with GLP-1 receptor agonists [see Adverse Reactions (6.2)]. If hypersensitivity reactions occur, advise the patient to promptly seek medical attention and discontinue use of FOUNDAYO.”
  9. 9.
    Trulicity prescribing information, section 6.1 (gastrointestinal adverse reactions)
    “In the pool of placebo-controlled trials, gastrointestinal (GI) adverse reactions occurred more frequently among patients who received TRULICITY compared to patients who received placebo (placebo 21%, 0.75 mg 32%, 1.5 mg 41%).”
  10. 10.
    Wegovy prescribing information, section 6.1 (gastrointestinal adverse reactions)
    “In clinical trials in adults for weight reduction, 73% of WEGOVY injection-treated patients and 47% of patients receiving placebo reported gastrointestinal adverse reactions, including severe reactions that were reported more frequently among patients receiving WEGOVY injection (4.1%) than placebo (0.9%).”
  11. 11.
    Wegovy prescribing information, section 6.1 (timing of gastrointestinal reactions)
    “These reactions were most frequently reported during dosage escalation.”
  12. 12.
    Wegovy prescribing information, section 2 (dosage escalation)
    “Follow the dosage escalation in Table 1 to reduce the risk of gastrointestinal adverse reactions. Table 1: Dosage Escalation, Weeks 5 through 8, 0.5 mg.”
  13. 13.
    Wegovy prescribing information, section 5 (acute pancreatitis)
    “After initiation of WEGOVY, observe patients carefully for signs and symptoms of acute pancreatitis, which may include persistent or severe abdominal pain (sometimes radiating to the back), and which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue WEGOVY and initiate appropriate management.”
  14. 14.
    Wegovy prescribing information, section 5 (acute kidney injury due to volume depletion)
    “Monitor renal function in patients reporting adverse reactions to WEGOVY that could lead to volume depletion, especially during dosage initiation and escalation of WEGOVY.”
  15. 15.
    Wegovy prescribing information, section 5 (pulmonary aspiration during general anesthesia or deep sedation)
    “Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking WEGOVY.”
  16. 16.
    Ozempic prescribing information, section 6.1 (gastrointestinal adverse reactions)
    “In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving OZEMPIC than placebo (placebo 15.3%, OZEMPIC 0.5 mg 32.7%, OZEMPIC 1 mg 36.4%). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation.”
  17. 17.
    Rybelsus and Ozempic tablets prescribing information, section 6.1 (gastrointestinal adverse reactions)
    “In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients who received semaglutide tablets than placebo: semaglutide tablets 14 mg once daily (41%), semaglutide tablets 7 mg once daily (32%) and placebo (21%), including severe reactions (semaglutide tablets 14 mg 2.0%, semaglutide tablets 7 mg 0.6%, placebo 0.3%). The majority of reports of nausea, vomiting and/or diarrhea occurred during dose escalation.”
  18. 18.
    Saxenda prescribing information, section 6.1 (gastrointestinal adverse reactions)
    “In the adult clinical trials, approximately 68% of SAXENDA-treated patients and 39% of placebo-treated patients reported gastrointestinal disorders; the most frequently reported was nausea (39% and 14% of patients treated with SAXENDA and placebo, respectively).”
  19. 19.
    Saxenda prescribing information, section 6.1 (discontinuation due to gastrointestinal reactions)
    “Most episodes of gastrointestinal events were mild or moderate and did not lead to discontinuation of therapy (6.2% with SAXENDA versus 0.8% with placebo discontinued treatment as a result of gastrointestinal adverse reactions). The percentage of patients reporting nausea declined as treatment continued.”
  20. 20.
    Saxenda prescribing information, section 5 (hypersensitivity reactions)
    “If a hypersensitivity reaction occurs, the patient should discontinue SAXENDA and other suspect medications and promptly seek medical advice.”
  21. 21.
    U.S. Food and Drug Administration: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition
    “The U.S. Food and Drug Administration is informing patients and health care providers of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. NAION is a rare condition that can result in acute, painless, decreased vision in one eye, including permanent vision loss. [...] The agency is requiring application holders for all GLP-1 RA medications to add information to the Warnings and Precautions section of labeling about the potential increased risk of NAION associated with use of these medications. [...] Patients should contact their health care professional right away if they have any of these symptoms. If a patient has had a NAION event, they should talk with their health care professional about whether to continue taking their GLP-1 RA medication or to stop it.”
  22. 22.
    FDA label (DailyMed): Zepbound prescribing information, section 4
    “ZEPBOUND is contraindicated in patients with: A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions (5.1)].”
  23. 23.
    FDA label (DailyMed): Mounjaro prescribing information, section 4
    “MOUNJARO is contraindicated in patients with: A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions (5.1)].”
  24. 24.
    FDA label (DailyMed): Foundayo prescribing information, section 4
    “FOUNDAYO is contraindicated in patients with: A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions (5.1)].”
  25. 25.
    FDA label (DailyMed): Trulicity prescribing information, section 4
    “TRULICITY is contraindicated in patients with: Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions (5.1)].”
  26. 26.
    FDA label (DailyMed): Wegovy prescribing information, section 4
    “a personal or family history of MTC or in patients with MEN 2”
  27. 27.
    FDA label (DailyMed): Ozempic prescribing information, section 4
    “A personal or family history of MTC or in patients with MEN 2”
  28. 28.
    FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 4
    “A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)”
  29. 29.
    FDA label (DailyMed): Saxenda prescribing information, section 4
    “Patients with a personal or family history of medullary thyroid carcinoma (MTC) or patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)”
  30. 30.
    FDA label (DailyMed): Zepbound prescribing information, section 5.2
    “ZEPBOUND is not recommended in patients with severe gastroparesis.”
  31. 31.
    FDA label (DailyMed): Mounjaro prescribing information, section 5.6
    “MOUNJARO is not recommended in patients with severe gastroparesis.”
  32. 32.
    FDA label (DailyMed): Foundayo prescribing information, section 5.3
    “FOUNDAYO is not recommended in patients with severe gastroparesis.”
  33. 33.
    FDA label (DailyMed): Trulicity prescribing information, section 5.6
    “TRULICITY is not recommended in patients with severe gastroparesis.”